Wedgewood Investors Inc. PA Reduces Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Wedgewood Investors Inc. PA lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,927 shares of the medical instruments supplier’s stock after selling 78 shares during the period. Wedgewood Investors Inc. PA’s holdings in Becton, Dickinson and were worth $681,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Ascent Wealth Partners LLC increased its holdings in shares of Becton, Dickinson and by 2.4% in the second quarter. Ascent Wealth Partners LLC now owns 31,523 shares of the medical instruments supplier’s stock worth $7,542,000 after purchasing an additional 741 shares during the period. Dai Ichi Life Insurance Company Ltd increased its holdings in shares of Becton, Dickinson and by 38.6% in the second quarter. Dai Ichi Life Insurance Company Ltd now owns 32,205 shares of the medical instruments supplier’s stock worth $7,706,000 after purchasing an additional 8,970 shares during the period. CWM LLC increased its holdings in shares of Becton, Dickinson and by 21.0% in the third quarter. CWM LLC now owns 2,019 shares of the medical instruments supplier’s stock worth $470,000 after purchasing an additional 351 shares during the period. Great West Life Assurance Co. Can increased its holdings in shares of Becton, Dickinson and by 1.5% in the second quarter. Great West Life Assurance Co. Can now owns 207,785 shares of the medical instruments supplier’s stock worth $49,525,000 after purchasing an additional 2,981 shares during the period. Finally, Page Arthur B increased its holdings in shares of Becton, Dickinson and by 7.4% in the third quarter. Page Arthur B now owns 10,155 shares of the medical instruments supplier’s stock worth $2,363,000 after purchasing an additional 698 shares during the period. Hedge funds and other institutional investors own 84.18% of the company’s stock.

Shares of NYSE:BDX traded up $0.15 on Monday, reaching $242.96. 20,634 shares of the company traded hands, compared to its average volume of 1,877,918. The business’s 50-day simple moving average is $235.11 and its 200 day simple moving average is $246.24. Becton, Dickinson and Company has a 52 week low of $197.75 and a 52 week high of $286.72. The stock has a market capitalization of $69.63 billion, a P/E ratio of 88.94, a price-to-earnings-growth ratio of 2.14 and a beta of 0.83. The company has a current ratio of 1.54, a quick ratio of 1.07 and a debt-to-equity ratio of 0.72.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.52 by $0.27. The firm had revenue of $4.78 billion for the quarter, compared to analysts’ expectations of $4.48 billion. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $3.31 earnings per share. Sell-side analysts expect that Becton, Dickinson and Company will post 12.5 EPS for the current fiscal year.

Several research analysts have recently weighed in on BDX shares. Morgan Stanley decreased their price target on shares of Becton, Dickinson and from $270.00 to $262.00 and set an “equal weight” rating on the stock in a report on Friday, November 6th. Raymond James reduced their target price on Becton, Dickinson and from $285.00 to $270.00 and set an “outperform” rating on the stock in a research note on Monday, October 12th. The Goldman Sachs Group raised Becton, Dickinson and from a “buy” rating to a “conviction-buy” rating in a research note on Friday, October 2nd. TheStreet cut Becton, Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, September 21st. Finally, UBS Group increased their target price on Becton, Dickinson and from $265.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $277.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Correction

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit